News
Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
2h
HealthDay on MSNRisk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, ObesityFor adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a ...
Buynetmeds.com has been sent a warning letter over the sale of opoioids and weight-loss drugs without a prescription.
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is independently associated with less improvement in glucose ...
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...
7h
Onlymyhealth on MSNOzempic Mouth: Understanding The Unwanted Side Effect Of The Weight-Loss MedicationIn recent times, medications like Ozempic (semaglutide) have gained popularity not only for managing type 2 diabetes but also ...
It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...
A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results